Satellos Bioscience Inc.
MSLE | NASDAQ
$6.70
-$0.12 (-1.69%)
At close: Oct 30, 2026, 4:00 PM ET
$6.82
+$0.12 (+1.79%)
After-hours:
Oct 30, 2026, 7:30 PM ET
-1.69%
(1D)No price chart data available for 1D timeframe.
Rating
15.8
-4.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1014/1028 (Top 99%)
Key Statistics
Market Data
Market Cap $8.63M
1D Range
6.43 6.93
52W Range
5.59 13.01
Valuation (TTM)
PE -3.49
PB 0.14
EV/EBITDA 1.50
Valuation (NTM)
Forward PE N/A
Forward PEG -0.04
Price Target $20.00
Cash Flow
FCF Yield -332.2%
SBC Adj. FCF Yield -352.6%
SBC Impact -6.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 11.8% |
35.6%
FCF 3Y | 5Y -12.8% |
-31.2%
Returns
ROA -53.2%
ROE -72.7%
ROIC -60.1%
Financial Health
Net Cash
$61.76M
Current Ratio 11.22
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an a...
Sector Healthcare
Industry Biotechnology
Employees 18
IPO Date Aug 3, 2012
Website satellos.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$18.00
Upside
+168.66%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove MSLE